



Press Release

Oxford Gene Technology and Applied InSilico Ltd announce development agreement

Oxford and Chippenham, UK, November 21, 2005. Oxford Gene Technology (OGT) and Applied InSilico (AI) announce a development agreement whereby AI will provide computational analysis services to OGT. AI will use its ELE™ (Evolutionary Learning Environment) software platform to analyse data generated from OGT's microarray technology and services.

In addition, as part of the agreement, the two companies will collaborate on a series of projects designed to deliver a range of new products and services for life science research.

James Clough, OGT's Commercial Director, said, "AI provides innovative solutions to analyse complex data sets which, combined with OGT's extensive knowledge of microarrays and their applications, provide a powerful combination to address the challenges of unravelling genetic complexity."

Commenting on the announcement, Clive Briant, AI's VP, Business Development, said, "This agreement really formalises an already excellent relationship between AI and OGT. We have worked closely together on several leading edge research projects and it is clear that OGT and AI have complementary technologies and similar goals to deploy their innovative solutions within the life science industry. For example, we are both interested in the possibilities surrounding predictive diagnostics and creating intelligent medical devices."

About OGT

Oxford Gene Technology (OGT) is a privately owned company founded in 1995 by Professor Sir Edwin Southern. The mission of the company is to develop advanced molecular tools for biologists and to make them widely available through licensing and service activities. The key business areas of OGT include

- licensing which has successfully provided access for a number of companies to OGT's fundamental intellectual property, particularly in the area of microarrays
- a services business which provides a flexible and cost-effective, customised DNA microarray service covering a range of applications and offers specialist support to assist customers with every aspect of their research
- Tridend, which is developing 'mass tags' to enhance the amount of information that researchers can generate from mass spectrometry experiments in proteomics and genomics
- Oxamer, which is generating novel array formats based on electrochemical deposition methods for use in life science and diagnostics

OGT's intellectual property covers four general areas that are relevant to the biological sciences; these incorporate microarrays, genomics, proteomics and electrochemistry.

About Applied InSilico

Founded in 2003, Applied InSilico dramatically reduces time and resources during drug discovery and development by providing uncompromised insight into complex disease data. Their ELE™ technology reveals verifiable relationships in the most complex of datasets in such areas as ADMET, genomics, proteomics, metabolomics research, and provides a holistic approach across the complete drug discovery pipeline.

For more information, visit www.appliedinsilico.com.

Further information:

Oxford Gene Technology

Oxford Gene Technology (Operations) Limited Begbroke Business and Science Park, Sandy Lane, Yarnton, Oxford, OX5 1PF UK Tel: +44 (0) 1865 856 340 Fax: +44 (0) 1865 379 433 Email: services@ogt.co.uk Web: www.ogt.co.uk	© 2005 kdm communications limited Editorial contact for further information or follow-up Sarah Withington at kdm communications limited , Bedford, UK Tel. +44 01234 210555 Fax: +44 01234 342397 email: ideas@kdm-communications.com
---	---

Applied InSilico:

UK contact Clive Briant marketing@appliedinsilico.com +44(0)1249 665923	US contact Debbie Brown Debbie@prguru.com 001 603 340 4059
--	--